ORGANIZATION
JPMA to Ponder Pricing System for New Modalities towards 2026 Reform: Chief
The Japan Pharmaceutical Manufacturers Association (JPMA) will discuss ways to craft a drug pricing system that appropriately reflects the value of new modalities in preparation for the FY2026 reimbursement reform, President Hiroaki Ueno said on February 15. Speaking at a…
To read the full story
ORGANIZATION
- Pharma Group Looks to Growth Strategy under Takaichi after Election Win
February 10, 2026
- Pharma Groups Call for Faster Diagnosis and R&D for Intractable, Rare Diseases
February 9, 2026
- Generic Industry Consolidation Opens Opportunities for CMOs: Industry Chief
February 6, 2026
- FIRM Warns Conditional Approval Pricing Change Could Chill Regenerative Medicine R&D
February 3, 2026
- AMDD to Continue Policy Advocacy to Address Device Lag and Loss: Chair
January 28, 2026
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…





